NeuroBo Pharmaceuticals Inc
NRBO
Get informed when a big investor buys or sells
+ FollowMarket Cap$14B
Close$
$4.38
85.8% upside
Current Fair Value
85.8% upsideUndervalued by 85.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.00 Billion |
|---|---|
| Enterprise Value | $13.99 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.35 |
| Beta | -0.28 |
| Outstanding Shares | 5,931,875,000 |
Return
| Return on Equity | -211.76% |
|---|---|
| Return on Assets | -108.85% |
| Return on Invested Capital | -217.03% |
Valuation & Multiples
| P/E Ratio | -0.35 |
|---|---|
| PEG | -1.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -930.65 |
| Enterprise Value to Net Income | -969 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 5, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NeuroBo Pharmaceuticals Inc
8 employees
CEO: Hyung Heon Kim Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading inv...